Navigation Links
Pharsight Expands Global Consulting Services Teams
Date:10/15/2007

New Hires and Expanded Internship Program Strengthen Strategic Consulting

Services, Reporting and Analysis Staff in Europe and Canada

MOUNTAIN VIEW, Calif., Oct. 15 /PRNewswire-FirstCall/ -- Pharsight Corporation (OTC Bulletin Board: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced the expansion of its scientific consulting services practices with three new hires. Pharsight has also expanded its internship program, which is designed to foster knowledge of modeling and simulation amongst graduate students in a variety of scientific disciplines.

Pharsight has hired Lars Lindbom, Ph.D., as a senior associate scientist in its Strategic Consulting Services (SCS) group, based in Europe. Dr. Lindbom joins Pharsight from Uppsala University's department of Pharmaceutical Biosciences in Sweden, where he held a postdoctoral research fellowship sponsored by Pfizer. He also served as a bioinformatics software systems developer within the discovery research organization at AstraZeneca. Dr. Lindbom has broad experience with population pharmacokinetic and pharmacodynamic (PK/PD) modeling and pharmacometric method development, with an emphasis in computer-intensive statistical methods.

Dr. Lindbom holds a Ph.D. from Uppsala University's department of Pharmaceutical Biosciences, within the National Network in Drug Development, Swedish Foundation for Strategic Research. Dr. Lindbom has authored or co- authored several original research articles in the field of pharmacostatistical modeling and has given invited presentations on Perl- speaks-NONMEM (PsN), a collection of computer programs aiding in the development of non-linear mixed effects models using NONMEM, to which he was a developer and remains an active contributor.

Pharsight's recently launched Reporting and Analysis Services (RAS) business unit has added a PK scientist in response to increased global demand for the group's PK/PD analysis and reporting services. The RAS team has also added a Quality Assurance Inspector to support delivery of high quality, regulatory-compliant clinical study analyses and reports for new drug approval. Since its launch in May 2007, the RAS unit has more than tripled its staff and has plans to expand its facilities in Montreal, Canada. In addition, the RAS unit has accepted into its internship program a student working towards a Ph.D. in Pharmaceutical Sciences at the University of Montreal.

"The addition of new expert staff in both the SCS and RAS business units will further enhance our ability to address the full spectrum of client needs in modeling and simulation," said Shawn O'Connor, president, chief executive officer and chairman of Pharsight. "Lars brings to SCS a wealth of expertise in the area of PK/PD modeling and advanced statistical methods. The addition of yet another talented, highly experienced scientist in the SCS group will help us meet the growing demand for applying model-based drug development approaches to support our client's decision-making processes."

"In addition to the expansion of the SCS team, we have continued to grow our RAS group's capabilities by bringing on new talent," continued Mr. O'Connor. "Requirements for regulatory-compliant analysis and reporting of PK/PD data to support new drug submissions has driven new customer demand for our RAS offering. We are pleased to extend Pharsight's internship program to cover our entire consulting services practice, which provides talented Ph.D. students with opportunities to work on projects and gain in-depth modeling and simulation expertise. We look forward to contributions from our newest colleagues that will further enhance the services that we provide to our clients."

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com.

Registered Trademarks and Trademarks

Pharsight is a registered trademark of Pharsight Corporation. All other brand or product names mentioned in this documentation are trademarks or registered trademarks of their respective companies or organizations.


'/>"/>
SOURCE Pharsight Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. The Cleveland Clinic Expands Its Services across the World via the Net
2. Ranbaxy Expands By Acquiring A Generic Company In Belgium
3. Insulin and Growth Hormone, Expands Life Span?
4. Health Insurance Company Expands Product Range
5. Bird Flu Outbreak Expands in Vietnam
6. Skin Cancer Research To Go Global
7. Dementia - a global problem
8. Obesity a global problem
9. Suggestions to reduce global heart disease burden
10. Drop in global deaths from measles
11. First global SARS meet opens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... ... for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of ... AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to ...
(Date:6/24/2016)... ... 24, 2016 , ... The Haute Beauty Network, affiliated with ... as a prominent plastic surgeon and the network’s newest partner. , Dr. ... handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands by ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... pluripotent stem (iPS) cells and other difficult to transfect cells, announces its launch ... PluriQ™ G9™ Gene Editing System is a complete system for culturing ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, InhaleLabs.com ... ingestion of their medication by matching users with high quality water pipes within an ... with no commitment. , Inhale was founded by two brothers, Nick and Mike Hunter, ...
(Date:6/23/2016)... ... June 23, 2016 , ... vcfo, a consulting firm ... pleased to announce the promotion of Mike Mackey to Regional Vice President of ... he was responsible for managing client projects and overseeing vcfo financial consultants in ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016  Consumers have taken a more active ... more emphasis on patient outcomes. ... the pharmaceutical industry have evolved beyond just providing ... are focusing on becoming more patient-oriented across their ... services that improve health. ...
(Date:6/24/2016)... N.J. , June 24, 2016  Collagen ... the design, development and manufacturing of collagen and ... regeneration announced today that Bill Messer ... and Marketing to further leverage the growing portfolio ... medical devices. Bill joins the Collagen ...
(Date:6/24/2016)... June 24, 2016  Global Blood Therapeutics, Inc. (GBT) ... developing novel therapeutics for the treatment of grievous ... the closing of its previously announced underwritten public ... the public offering price of $18.75 per share. ... offered by GBT. GBT estimates net proceeds from ...
Breaking Medicine Technology: